Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment.

ABSTRACT:

Background

Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response.

Objectives

To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF.

Methods

CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple

SUBMITTER: Leurs CE 

PROVIDER: S-EPMC5987988 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature